OCA
CALT

Octagon Capital Advisors’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Octagon Capital Advisors’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-200,000
Closed -$6.72M – 36
2020
Q4 		$6.72M Buy
+200,000
New +$6.09M 2.33% 16

Other funds holding CALT

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Octagon Capital Advisors's CALT Position: Q1 2021 in Review

Octagon Capital Advisors sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q1 2021, closing a stake of 200,000 shares — an estimated $6.72M sold.

Octagon Capital Advisors first reported a position in CALT in Q4 2020 and held it in 1 quarter. The position peaked at $6.72M in Q4 2020. 14 funds tracked by Wall St. Rank hold CALT as of Q1 2021.

  • Octagon Capital Advisors reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q1 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 200,000 Calliditas Therapeutics AB American Depositary Shares shares in Q1 2021, an estimated $6.72M.
  • Octagon Capital Advisors first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q4 2020 and held it in 1 quarter.
  • Octagon Capital Advisors's Calliditas Therapeutics AB American Depositary Shares position peaked at $6.72M in Q4 2020.
  • 14 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q1 2021.

Based on Octagon Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.